InMed Pharmaceuticals - Termination of coverage
Edison Investment Research is terminating coverage on Steakholder Foods (formerly known as MeaTech) (MITC), Mesoblast (MSB), Bluglass (BLG), InMed...
669 Views
InMed Pharmaceuticals - THCV launch expands rare cannabinoids portfolio
InMed Pharmaceuticals has announced the launch of tetrahydrocannabivarin (d9-THCV) into B2B sales for the health and wellness industry. This marks...
671 Views
InMed Pharmaceuticals - Health and wellness product launches
InMed Pharmaceuticals has reported fiscal Q322 results (ending 31 March) benefiting from commercial sales into the health and wellness market. Its...
672 Views
InMed Pharmaceuticals - Notable launches of high-value rare cannabinoids
InMed Pharmaceuticals (INM) continues its transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the...
16 Views
InMed Pharmaceuticals - Generating commercial sales of CBC and CBT
InMed Pharmaceuticals’ (INM’s) Q222 financial results reflect its evolution from a pure-play biotech firm to one with commercial sales to the...
965 Views